Development of RApid Point-of-Care test Platforms for Infectious Diseases
RAPP-ID (Development of RApid Point-of-Care test Platforms for Infectious Diseases”) will develop a Point-of-Care Test (POCT) for rapid (hospital <2h, primary care <30min) detection of bacteria, mycobacteria, fungi, as well as vir...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PID2020-118904RB-C22
DESARROLLO DE TESTS RAPIDOS Y ULTRASENSIBLES PARA INFECCIONE...
74K€
Cerrado
PLEC2021-007739
Biosensores nanofotónicos para el diagnóstico y gestión clín...
370K€
Cerrado
Molecular Culture
World’s first diagnostic test that can detect all bacterial...
5M€
Cerrado
PTQ-15-07422
Nuevos ensayos de PCR para la detección rápida y eficaz de g...
84K€
Cerrado
PTQ-17-09111
Desarrollo de un inmunoensayo ultrasensible y multiplexado p...
57K€
Cerrado
PRONTO
self-PoweRed cONductimeter for digiTalization of rapid mOlec...
150K€
Cerrado
Información proyecto RAPP-ID
Duración del proyecto: 65 meses
Fecha Inicio: 2011-04-01
Fecha Fin: 2016-09-30
Descripción del proyecto
RAPP-ID (Development of RApid Point-of-Care test Platforms for Infectious Diseases”) will develop a Point-of-Care Test (POCT) for rapid (hospital <2h, primary care <30min) detection of bacteria, mycobacteria, fungi, as well as viruses and host biomarkers by combining novel specific probes, novel methods of sample preparation, and demonstrated ultra-high sensitive detection methods. The platforms will also determine resistance to antimicrobial drugs. The research will focus on the biomarkers and pathogens involved in 1) Sepsis, 2) Lower Respiratory Tract Infections (LRTI), including Community-Acquired Pneumonia (CAP) and Ventilator-Associated Pneumonia (VAP), and 3) Tuberculosis (TB). Detection of bacteria, fungi and antibiotic resistance will mainly involve Nucleic Acid (NA) tests, whereas viral and host biomarker detection will mainly involve selective immunobinding with a probe or with a sensor surface. The diagnostic tests consist of in four functional modules: 1) sample collection and interfacing, 2) upconcentration and extraction, 3) signal and/or sample amplification, and 4) detection. RAPP-ID will integrate the minimum number of modules required for each disease/syndrome in a microfluidic cartridge, for which a breadboard reader with Graphical User Interface (GUI) provides the necessary optical/fluidic/electric/thermal interfaces. The integrated POCT will be validated on (spiked) reference samples and well characterised clinical samples and compared with the best reference standards and other standard available diagnostic tests.